Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation

English version České info

The accumulation of aggregated proteins in the brain is common across several neurodegenerative disorders. In Parkinson's disease (PD), the protein alpha-synuclein (ASYN) is the major component of aggregates known as Lewy bodies. It is currently unclear whether protein aggregates are protective or detrimental for neuronal function and survival. The present hypothesis is that smaller aggregated species, known as oligomers, might constitute the toxic forms of ASYN. Several mutations in ASYN cause familial forms of PD. In the laboratory, artificial mutations have been designed to enable the study of the aggregation process. However, different studies relied on the use of different model systems, compromising the interpretation of the effects of the mutations. Here, we addressed this by (i) assembling a panel of 19 ASYN variants and (ii) by performing a systematic comparison of the effects of the mutations in mammalian cell models. Interestingly, our study enabled us to correlate oligomerization and aggregation of ASYN in cells. Altogether, our data shed light into the molecular determinants of ASYN aggregation, opening novel avenues for the identification of modulators of ASYN aggregation, which conceal great hopes towards the development of strategies for therapeutic intervention in PD and other synucleinopathies.

Vyšlo v časopise: Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation. PLoS Genet 10(11): e32767. doi:10.1371/journal.pgen.1004741
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1004741

Souhrn

Zdroje

1. BurreJ, SharmaM, TsetsenisT, BuchmanV, EthertonMR, et al. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329: 1663–1667.

2. SpillantiniMG, SchmidtML, LeeVM, TrojanowskiJQ, JakesR, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839–840.

3. GoedertM, SpillantiniMG, Del TrediciK, BraakH (2013) 100 years of Lewy pathology. Nat Rev Neurol 9: 13–24.

4. de RijkMC, TzourioC, BretelerMM, DartiguesJF, AmaducciL, et al. (1997) Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62: 10–15.

5. PolymeropoulosMH, LavedanC, LeroyE, IdeSE, DehejiaA, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045–2047.

6. KrugerR, KuhnW, MullerT, WoitallaD, GraeberM, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106–108.

7. ZarranzJJ, AlegreJ, Gomez-EstebanJC, LezcanoE, RosR, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164–173.

8. SingletonAB, FarrerM, JohnsonJ, SingletonA, HagueS, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.

9. Chartier-HarlinMC, KachergusJ, RoumierC, MourouxV, DouayX, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167–1169.

10. IbanezP, BonnetAM, DebargesB, LohmannE, TisonF, et al. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169–1171.

11. FarrerM, KachergusJ, FornoL, LincolnS, WangDS, et al. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55: 174–179.

12. Simon-SanchezJ, SchulteC, BrasJM, SharmaM, GibbsJR, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308–1312.

13. NallsMA, PlagnolV, HernandezDG, SharmaM, SheerinUM, et al. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377: 641–649.

14. KielyAP, AsiYT, KaraE, LimousinP, LingH, et al. (2013) alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 125: 753–769.

15. LesageS, AnheimM, LetournelF, BoussetL, HonoreA, et al. (2013) G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 73: 459–471.

16. ProukakisC, DudzikCG, BrierT, MacKayDS, CooperJM, et al. (2013) A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80: 1062–1064.

17. KhalafO, FauvetB, OueslatiA, DikiyI, Mahul-MellierAL, et al. (2014) The H50Q mutation enhances alpha-synuclein aggregation, secretion and toxicity. J Biol Chem 289: 21856–21876.

18. MarquesO, OuteiroTF (2012) Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3: e350.

19. LashuelHA, OverkCR, OueslatiA, MasliahE (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14: 38–48.

20. ConwayKA, LeeSJ, RochetJC, DingTT, WilliamsonRE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571–576.

21. FredenburgRA, RospigliosiC, MerayRK, KesslerJC, LashuelHA, et al. (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46: 7107–7118.

22. GoncalvesS, OuteiroTF (2013) Assessing the Subcellular Dynamics of Alpha-synuclein Using Photoactivation Microscopy. Mol Neurobiol 47: 1081–1092.

23. OuteiroTF, LindquistS (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302: 1772–1775.

24. CaiH, ReinischK, Ferro-NovickS (2007) Coats, tethers, Rabs, and SNAREs work together to mediate the intracellular destination of a transport vesicle. Dev Cell 12: 671–682.

25. MurphyDD, RueterSM, TrojanowskiJQ, LeeVM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20: 3214–3220.

26. KluckenJ, PoehlerAM, Ebrahimi-FakhariD, SchneiderJ, NuberS, et al. (2012) Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 8: 754–766.

27. Hernandez-VargasR, Fonseca-OrnelasL, Lopez-GonzalezI, Riesgo-EscovarJ, ZuritaM, et al. (2011) Synphilin suppresses alpha-synuclein neurotoxicity in a Parkinson's disease Drosophila model. Genesis 49: 392–402.

28. BoniniNM, GiassonBI (2005) Snaring the function of alpha-synuclein. Cell 123: 359–361.

29. VekrellisK, XilouriM, EmmanouilidouE, RideoutHJ, StefanisL (2011) Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 10: 1015–1025.

30. McDowellK, ChesseletMF (2012) Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis 46: 597–606.

31. LowK, AebischerP (2012) Use of viral vectors to create animal models for Parkinson's disease. Neurobiol Dis 48: 189–201.

32. BezardE, PrzedborskiS (2011) A tale on animal models of Parkinson's disease. Mov Disord 26: 993–1002.

33. FujiwaraH, HasegawaM, DohmaeN, KawashimaA, MasliahE, et al. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160–164.

34. OkochiM, WalterJ, KoyamaA, NakajoS, BabaM, et al. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 275: 390–397.

35. PaleologouKE, SchmidAW, RospigliosiCC, KimHY, LambertoGR, et al. (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 283: 16895–16905.

36. TaschenbergerG, GarridoM, TereshchenkoY, BahrM, ZweckstetterM, et al. (2012) Aggregation of alphaSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol 123: 671–683.

37. DorvalV, FraserPE (2006) Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem 281: 9919–9924.

38. KrumovaP, MeulmeesterE, GarridoM, TirardM, HsiaoHH, et al. (2011) Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 194: 49–60.

39. ShultsCW (2006) Lewy bodies. Proc Natl Acad Sci U S A 103: 1661–1668.

40. KarpinarDP, BalijaMB, KuglerS, OpazoF, Rezaei-GhalehN, et al. (2009) Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J 28: 3256–3268.

41. WinnerB, JappelliR, MajiSK, DesplatsPA, BoyerL, et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108: 4194–4199.

42. OuteiroTF, PutchaP, TetzlaffJE, SpoelgenR, KokerM, et al. (2008) Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE 3: e1867.

43. McLeanPJ, KawamataH, HymanBT (2001) Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 104: 901–912.

44. TenreiroS, MunderMC, AlbertiS, OuteiroTF (2013) Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. J Neurochem 127: 438–452.

45. LeeHJ, LeeSJ (2002) Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 277: 48976–48983.

46. DanzerKM, RufWP, PutchaP, JoynerD, HashimotoT, et al. (2011) Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 25: 326–336.

47. RemyI, MichnickSW (2006) A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat Methods 3: 977–979.

48. BorghiR, MarcheseR, NegroA, MarinelliL, ForloniG, et al. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287: 65–67.

49. El-AgnafOM, SalemSA, PaleologouKE, CooperLJ, FullwoodNJ, et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17: 1945–1947.

50. KruseN, Schulz-SchaefferWJ, SchlossmacherMG, MollenhauerB (2012) Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of alpha-synuclein and other proteins in cerebrospinal fluid. Methods 56: 514–518.

51. GonatasNK, StieberA, GonatasJO (2006) Fragmentation of the Golgi apparatus in neurodegenerative diseases and cell death. J Neurol Sci 246: 21–30.

52. FanJ, HuZ, ZengL, LuW, TangX, et al. (2008) Golgi apparatus and neurodegenerative diseases. Int J Dev Neurosci 26: 523–534.

53. FujitaY, OhamaE, TakatamaM, Al-SarrajS, OkamotoK (2006) Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Acta Neuropathol 112: 261–265.

54. HoltzWA, O'MalleyKL (2003) Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 278: 19367–19377.

55. HetzC (2012) The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 13: 89–102.

56. ChenL, FeanyMB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8: 657–663.

57. PandeyN, SchmidtRE, GalvinJE (2006) The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp Neurol 197: 515–520.

58. FaresMB, Ait-BouziadN, DikiyI, MbefoMK, JovicicA, et al. (2014) The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet 23: 4491–4509.

59. Rutherford NJ, Moore BD, Golde TE, Giasson BI (2014) Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein. J Neurochem. E-pub ahead of print. doi:10.1111/jnc.12806

60. TrexlerAJ, RhoadesE (2010) Single molecule characterization of alpha-synuclein in aggregation-prone states. Biophys J 99: 3048–3055.

61. ChenL, PeriquetM, WangX, NegroA, McLeanPJ, et al. (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119: 3257–3265.

62. OueslatiA, PaleologouKE, SchneiderBL, AebischerP, LashuelHA (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J Neurosci 32: 1536–1544.

63. PaleologouKE, OueslatiA, ShakkedG, RospigliosiCC, KimHY, et al. (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30: 3184–3198.

64. El-AgnafOM, JakesR, CurranMD, MiddletonD, IngenitoR, et al. (1998) Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 440: 71–75.

65. HejjaouiM, ButterfieldS, FauvetB, VercruysseF, CuiJ, et al. (2012) Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: alpha-synuclein phosphorylation at tyrosine 125. J Am Chem Soc 134: 5196–5210.

66. GosaviN, LeeHJ, LeeJS, PatelS, LeeSJ (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 277: 48984–48992.

67. PetroiD, PopovaB, Taheri-TaleshN, IrnigerS, ShahpasandzadehH, et al. (2012) Aggregate clearance of alpha-synuclein in S. cerevisiae depends more on autophagosome and vacuole function than on the proteasome. J Biol Chem 287: 27567–27579.